Christine Coyne, MBA

Vice President of Marketing, BTG Specialty Pharmaceuticals

In 1996, Christine Coyne began her marketing career as an Associate Product Manager with Wyeth-Ayerst Global Pharmaceuticals in the Infant Nutritionals Division with responsibility for core strategic marketing, public relations and promotional programs for the franchise’s base brand, S-26. For years, Christine held various positions of increasing responsibility until her ultimate position in 1999 as Product Manager.

In 1999, Christine expanded her marketing background to include advertising by joining The Hal Lewis Group, a healthcare marketing communications agency, where she had responsibilities for managing several major pharmaceutical accounts including Merck, Pharmacia and AstraZeneca. 

In 2000, Christine re-joined Wyeth in the Healthcare Systems Marketing department with responsibility for developing strategies and tactics to communicate the clinical benefits of Wyeth’s brands, Effexor XR, Protonix, and Altace, in order to obtain/maintain positive formulary placement and increased utilization.

Christine took a leadership role in the development and implementation of a senior care business plan for Wyeth and was awarded two President’s Awards for her efforts during 2001 and 2002. 

From 2003 to 2005, Christine contributed to the Effexor XR US Brand team with multiple responsibilities, but largely focused on communication efforts with patients. In 2005, Christine was invited to work on the Enbrel Global Rheumatology Brand Team. This work included developing the first global HCP campaign for Enbrel that was adopted worldwide. After her work on the global rheumatology business, Christine continued her global work by accepting a Director of Commercial Operations position within Latin America. This role allowed Christine to leverage her years of marketing experience with the HCP, Patients and Payors. In this role, Christine managed the strategic direction and tactical implementation for Prevenar (PCV 7), infant pneumococcal conjugate vaccine, as well as the upcoming launch of PCV 13 (13 valent).

After 17 years of contributing to many of the different Wyeth business units, Christine undertook a new challenge at Endo Pharmaceuticals. In 2008, Christine was responsible for overall brand management of Voltaren® Gel (1% diclofenac gel), which attained $250MM net sales under her leadership. In 2010, Christine was promoted to Senior Director, Adult Endocrinology. In this new role, Christine managed the Adult Endocrinology product portfolio, which included three testosterone replacement products.

In 2011, Christine joined Auxilium Pharmaceuticals as a Senior Director with responsibility of managing the XIAFLEX® product portfolio and Marketing Support teams.

In 2014, Christine joined BTG as Vice President of Marketing for Specialty Pharmaceuticals where she is responsible for more than $250MM net sales across 3 commercialized products and 2 near-term pipeline products, as well as Global Operations.

  • Christine holds a Master Degree in Business Administration from Eastern University as well as a Bachelor’s Degree in Foreign Languages from West Chester University.
  • Christine has taught as an Adjunct Professor of Marketing at West Chester University.
  • Christine has participated as a Board Member of MM&M Editorial Advisory Board since 2011.
  • Christine is a Board Member of University of Pennsylvania Women’s Health Leadership Council
  • Christine is a Fellow at Columbia University HITLab